MedTrace Logo

Comparison of Carvedilol and Atorvastatin for Preventing of Contrast-Induced Nephropathy.

NCT03867994 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 144

Last updated 2019-03-12

No results posted yet for this study

Summary

This prospective study is intended to evaluate if carvedilol has any potential protective effect over atorvastatin on the development of contrast-induced nephropathy (CIN) following cardiac catheterization in patients with moderate to high risk for CIN.

Conditions

  • Contrast-induced Nephropathy

Interventions

DRUG

Atorvastatin

DRUG

Carvedilol

DRUG

saline

Sponsors & Collaborators

  • Cairo University

    collaborator OTHER

  • rabab ahmed mohamed

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-01
Primary Completion
2017-05-15
Completion
2017-05-15

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03867994 on ClinicalTrials.gov